Tenaya Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance
Tenaya Therapeutics, Inc. (TNYA) had Deferred Tax Assets, Valuation Allowance of $146.13 million as of 2025-12-31, per its 10-K filed 2026-03-11.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsValuationAllowance · last filed 2026-03-11
- 2025-12-31: Deferred Tax Assets, Valuation Allowance $146.13M.
- 2024-12-31: Deferred Tax Assets, Valuation Allowance $126.33M.
- 2023-12-31: Deferred Tax Assets, Valuation Allowance $101.29M.
- 2022-12-31: Deferred Tax Assets, Valuation Allowance $71.13M.
| Period end | Deferred Tax Assets, Valuation Allowance |
|---|---|
| 2025-12-31 | $146.13M 10-K · filed 2026-03-11 |
| 2024-12-31 | $126.33M 10-K · filed 2026-03-11 |
| 2023-12-31 | $101.29M 10-K · filed 2025-03-10 |
| 2022-12-31 | $71.13M 10-K · filed 2024-03-18 |
| 2021-12-31 | $41.28M 10-K · filed 2023-03-08 |
| 2020-12-31 | $24.29M 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |